Logo image of CDTX

CIDARA THERAPEUTICS INC (CDTX) Stock Fundamental Analysis

NASDAQ:CDTX - US1717572069 - Common Stock

65.23 USD
-0.16 (-0.24%)
Last: 8/28/2025, 8:00:02 PM
65.23 USD
0 (0%)
After Hours: 8/28/2025, 8:00:02 PM
Fundamental Rating

3

Overall CDTX gets a fundamental rating of 3 out of 10. We evaluated CDTX against 547 industry peers in the Biotechnology industry. CDTX has a great financial health rating, but its profitability evaluates not so good. CDTX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CDTX had negative earnings in the past year.
In the past year CDTX has reported a negative cash flow from operations.
In the past 5 years CDTX always reported negative net income.
In the past 5 years CDTX always reported negative operating cash flow.
CDTX Yearly Net Income VS EBIT VS OCF VS FCFCDTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

CDTX's Return On Assets of -21.99% is fine compared to the rest of the industry. CDTX outperforms 75.69% of its industry peers.
CDTX has a better Return On Equity (-23.44%) than 82.27% of its industry peers.
Industry RankSector Rank
ROA -21.99%
ROE -23.44%
ROIC N/A
ROA(3y)-61.33%
ROA(5y)-72.86%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CDTX Yearly ROA, ROE, ROICCDTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K

1.3 Margins

CDTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CDTX Yearly Profit, Operating, Gross MarginsCDTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

8

2. Health

2.1 Basic Checks

CDTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CDTX has more shares outstanding
Compared to 5 years ago, CDTX has more shares outstanding
The debt/assets ratio for CDTX has been reduced compared to a year ago.
CDTX Yearly Shares OutstandingCDTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
CDTX Yearly Total Debt VS Total AssetsCDTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 28.63 indicates that CDTX is not in any danger for bankruptcy at the moment.
The Altman-Z score of CDTX (28.63) is better than 95.98% of its industry peers.
CDTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 28.63
ROIC/WACCN/A
WACC9.7%
CDTX Yearly LT Debt VS Equity VS FCFCDTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

A Current Ratio of 16.45 indicates that CDTX has no problem at all paying its short term obligations.
The Current ratio of CDTX (16.45) is better than 91.41% of its industry peers.
A Quick Ratio of 16.45 indicates that CDTX has no problem at all paying its short term obligations.
CDTX has a Quick ratio of 16.45. This is amongst the best in the industry. CDTX outperforms 91.41% of its industry peers.
Industry RankSector Rank
Current Ratio 16.45
Quick Ratio 16.45
CDTX Yearly Current Assets VS Current LiabilitesCDTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

CDTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -77.51%.
Looking at the last year, CDTX shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
CDTX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -42.85% yearly.
EPS 1Y (TTM)-77.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.71%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-70.48%
Revenue growth 5Y-42.85%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 11.26% on average over the next years. This is quite good.
The Revenue is expected to grow by 95.15% on average over the next years. This is a very strong growth
EPS Next Y40.14%
EPS Next 2Y13.6%
EPS Next 3Y11.72%
EPS Next 5Y11.26%
Revenue Next Year-100%
Revenue Next 2Y-19.19%
Revenue Next 3Y-6.54%
Revenue Next 5Y95.15%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CDTX Yearly Revenue VS EstimatesCDTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2019 2020 2021 2022 2023 2024 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
CDTX Yearly EPS VS EstimatesCDTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CDTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CDTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CDTX Price Earnings VS Forward Price EarningsCDTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CDTX Per share dataCDTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.6%
EPS Next 3Y11.72%

More info and screens

0

5. Dividend

5.1 Amount

CDTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CIDARA THERAPEUTICS INC

NASDAQ:CDTX (8/28/2025, 8:00:02 PM)

After market: 65.23 0 (0%)

65.23

-0.16 (-0.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05
Inst Owners79.79%
Inst Owner Change168.4%
Ins Owners1%
Ins Owner Change0.3%
Market Cap1.65B
Analysts84.62
Price Target75.48 (15.71%)
Short Float %10.97%
Short Ratio2.5
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.36%
Min EPS beat(2)18.65%
Max EPS beat(2)54.07%
EPS beat(4)3
Avg EPS beat(4)17.69%
Min EPS beat(4)-45.43%
Max EPS beat(4)54.07%
EPS beat(8)6
Avg EPS beat(8)-97.67%
EPS beat(12)7
Avg EPS beat(12)-52.11%
EPS beat(16)10
Avg EPS beat(16)-34.77%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)25.07%
PT rev (3m)94.74%
EPS NQ rev (1m)25.91%
EPS NQ rev (3m)41.59%
EPS NY rev (1m)15.2%
EPS NY rev (3m)16.42%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.3
P/tB 3.3
EV/EBITDA N/A
EPS(TTM)-11.13
EYN/A
EPS(NY)-8.15
Fwd EYN/A
FCF(TTM)-5.09
FCFYN/A
OCF(TTM)-5.09
OCFYN/A
SpS0
BVpS19.76
TBVpS19.76
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.99%
ROE -23.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.33%
ROA(5y)-72.86%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.45
Quick Ratio 16.45
Altman-Z 28.63
F-Score3
WACC9.7%
ROIC/WACCN/A
Cap/Depr(3y)188.62%
Cap/Depr(5y)130.51%
Cap/Sales(3y)3.7%
Cap/Sales(5y)2.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-77.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.71%
EPS Next Y40.14%
EPS Next 2Y13.6%
EPS Next 3Y11.72%
EPS Next 5Y11.26%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-70.48%
Revenue growth 5Y-42.85%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-19.19%
Revenue Next 3Y-6.54%
Revenue Next 5Y95.15%
EBIT growth 1Y-241.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year19.62%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-9652.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-11576%
OCF growth 3YN/A
OCF growth 5YN/A